Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0
članak: 10 od 13  
Back povratak na rezultate
Vojnosanitetski pregled
2001, vol. 58, br. 1, str. 65-72
jezik rada: srpski
vrsta rada: pregledni članak

Inhibitori trombocitnog glikoproteina IIb/IIIa u kardiologiji
Vojnomedicinska akademija

Sažetak

Članak ne sadrži sažetak.

Ključne reči

koronarna, bolest; miokard, ishemija; glikoproteini trombocita, GP Ilb/IIIa kompleks; andagregaciona sredstva

Reference

Naknadno pridodat članak: provera, normiranje i linkovanje referenci u toku.
Antman E, Braunwald E, editor. Acute myocardial infarction. In Braunwald E: A textbook of cardiovascular disease. [Monograph on CD-ROM], Philadelphia: W.B.Saunders; 1998. p. 1184-288.
White HD. Unstable angina: ischemic Syndromes. In Topol E, Nissen S, editors. Cardiovascular medicine [Monograph on CD-ROM]. Philadelphia: Lippincott - Raven; 1998. 395-424.
Topol E, Wan de Werf FJ. Acute myocardial infarction and management. In: Topol E and Nissen S, editors. Cardiovascular medicine. Monograph on CD-ROM. Philadelphia: Lippincott Raven; 1998. p. 425-66.
Topol EJ, Califf RM, Weisman HF, Ellis SG, Toheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet Ilb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
Platelet glycoprotein IIb/IIIа receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. N Engl J Med 1997; 336:1689-96.
Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997; 349: 1429-35.
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIla blockade. The EPISTENT Investigators. Evaluation of Platelet Ilb/IIIa inhibitor for Stenting. Lancet 1998; 352: 87-92.
Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, et al. Randomised, placebo-controlled trial of platelet glycoprotein Ilb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PT CA Organization and Randomized Trial (RAPPORT) investigators. Circulation 1998; 98: : 734-41.
Campbell KR, Cantor W, Sketch M, Ohman M. Glycoprotein Ilb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. Am Heart J 2000; 140:115-24.
Foster RH, Wiseman LR. Abciximab. An updated review of its use in ischaemic heart disease. Drugs 1998; 56: 629-65.
Coller BS. GPIIb/IIIa antagonists: pathophisiologic and therapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997; 78: 730-5.
Altieri DC, Edginton TS. A monoclonal antibody reacting to distinct adhesion molecules defines a transition in the stational state of the receptor CD11b/CD18 (MAC-1). J Immunol 1988; 141: 2656-60.
Konstantopoulos K, Kamat SG, Schafer AI, Banez El, Jordan R, Kleiman NS, et al. Shear-induced platelet aggregation is inhibited by in vivo infusion of an antiglycoprotein Ilb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty. Circulation 1995; 91:1427-31.
Carr ME, Carr SL, Hantgan RR, Braaten J. Glycoprotein Ilb/IIIa blockade inhibits platelet-mediated force development and reduces gel elastic modules. Thromb Haemost 1995; 73: 499-505.
Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein Ilb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-7.
Cooler BS. Binding of abciximab to lafa Vbeta3 and activated alfaMbeta2 receptors: with review of platelet-leukocyte interactions. Thromb Haemost 1999; 82: : 326-36.
Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody against the platelet glycoprotein Ilb/Illa cross-link with the leukocyte integrin Mac-1 and blocks adhesion of fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-35.
Tsao PW, Forsythe MS, Mousa SA. Dissociation between the anti-aggregatory & anti-secretory effects of platelet integrin alphallbbeta3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb 1997; 88: 137-46.
Liem TK, Teel R, Shuckla S, Silver D. The glycoprotein Ilb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies. J Vasc Surg 1997; 25:124-30.
Lefkovits J, Ivanhoe RJ, Calijf RM, Bergelson BA, Anolerson KM, Stoner GL, et al. Effects of glycoprotein Ilb/IIIa blockade by a chimeric monoclonal antibody (abciximab) on acute and six months outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996; 77: : 1045-51.
Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. New Engl J Med 1999; 340:: 1623-9.
Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet Ilb/IIIa Inhibition for Prevention Ischemic Complication. JAMA 1997; 278:: 479-84.
Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999; 99: : 2720-32.
Goa KL, Noble S. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999; 57:439-62.
Inhibition of platelet glycoprotein Ilb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation. Platelet Glycoprotein Ilb/IIIa in Unstable Angina: Receptor Supression Using Integrelin Therapy. The PURSUIT Trial Investigators. N Eng J Med 1998; 339: 436-43.
Randomised placebo-controlled trial of effect of eptifibatide on complication of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349:1422-8.
Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95: 846-54.
Goan KL, Noble S. Eptifibatide. A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999; 57: 439-62.
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management. (PRISM) Study Investigators. New Engl J Med 1998; 338: : 1498-505.
Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. New Engl J Med 1998; 338: : 1488-97
Effects of platelet glycoprotein Ilb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation 1997; 96:1445-53.
International, randomized, controlled trial of Lamifiban (a platelet glycoprotein II/b/IIIa inhibitor), Heparin, or both in unstable angina. The PARAGON Investigators. Platelet Ilb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998; 97: : 2386-95.
Combining thrombolysis with the platelet glycoprotein Ilb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. J Am Coll Cardiol 1998; 32: : 2003-10.
O'Neill WW, Serruys P, Knudtson M, van Es GA, vender Zwmn C, Timmis GC, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.New Engl J Med 2000; 342: : 1316-24.
Newby LK Long-term oral platelet glycoprotein Ilb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee. Am Heart J 1999; 138:210-8.
Ferguson JJ. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology. Circulation 1999; 100: 570-5.
Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy, orbofibn in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol 2000; 85:491-3.
Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999; 353: 227-31.